Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Examine APL-130277 in Patients With Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02228590
Recruitment Status : Completed
First Posted : August 29, 2014
Results First Posted : July 30, 2020
Last Update Posted : July 30, 2020
Sponsor:
Information provided by (Responsible Party):
Sunovion

Brief Summary:
The primary objective of this study is to evaluate the efficacy, tolerability and safety of single treatments of APL-130277 in 16 patients with Parkinson's Disease (PD)

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: APL-130277 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease
Actual Study Start Date : August 31, 2014
Actual Primary Completion Date : November 24, 2014
Actual Study Completion Date : November 24, 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
APL-130277
open label baseline comparison
Drug: APL-130277
Apomorphine Hydrochloride, Sublingual Thin Film
Other Name: Apomorphine Hydrochloride, Sublingual Thin Film




Primary Outcome Measures :
  1. The Percentage of Patients With Resolution of an 'OFF' Episode to an 'ON' State Following Administration of APL-130277 [ Time Frame: At 15, 30, 45, 60 and 90 minutes after dosing at Visits 3 - 5. ]
    Clinical confirmation of an 'OFF' state was assessed prior to dosing and confirmation of 'OFF' or 'ON' was assessed after dosing at Visits 3 - 5 by the Investigator. The first full 'ON' dose was defined as the earliest dose in which a patient achieved a full 'ON' state as assessed by the Investigator. The percentage of patients who achieved their first full 'ON' is presented for each timepoint, regardless of the dose received, and for the study overall (i.e. all post-dose timepoints).

  2. Time to 'ON' State From Time of Dosing of APL-130277 [ Time Frame: At 15, 30, 45, 60 and 90 minutes after dosing at Visits 3 - 5. ]
    Clinical confirmation of 'OFF' or 'ON' was assessed after dosing at Visits 3 - 5 by the Investigator. The time to the full 'ON' state from the time of dosing in minutes was calculated from timings noted by the Investigator and recorded in the electronic case report form (eCRF). The mean time taken for a patient to reach their first full 'ON' state following administration of APL-130277 is presented for patients who turned 'ON' for the study overall.

  3. Duration of 'ON' Response From Time of Dosing of APL-130277 [ Time Frame: At 15, 30, 45, 60 and 90 minutes after dosing at Visits 3 - 5. ]
    Clinical confirmation of 'OFF' or 'ON' was assessed after dosing at Visits 3 - 5 by the Investigator. The duration of the 'ON' response was defined as the length of time in which a patient was confirmed 'ON' within a dose, and was calculated from the time noted by the Investigator and recorded in the eCRF. The mean duration of the first full 'ON' response following administration of APL-130277 is presented for patients who turned 'ON' for the study overall.

  4. Percentage of Patients Who Completed the Trial and Experienced an 'ON' Episode [ Time Frame: At 15, 30, 45, 60 and 90 minutes after dosing at Visits 3 - 5. ]
    Clinical confirmation of 'OFF' or 'ON' was assessed after dosing at Visits 3 - 5 by the Investigator. For the overall study, the percentage of patients who completed the trial, and who experienced an 'ON' episode is presented.

  5. Pharmacokinetic (PK) Evaluation: Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Just prior to dosing and at 10, 20, 30, 45, 60 and 90 minutes after each dose at Visits 3 - 5. ]

    The mean Cmax values are presented for each dosage administered at Visits 3, 4, and 5 for which data was available.

    Plasma concentrations of the active substance of APL-130277, apomorphine, were analysed using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay, with a lower limit of quantification of 0.020 nanograms per millilitre (ng/mL).


  6. PK Evaluation: Time of Maximum Observed Plasma Concentration (Tmax) [ Time Frame: Just prior to dosing and at 10, 20, 30, 45, 60 and 90 minutes after each dose at Visits 3 - 5. ]

    The median Tmax values are presented for each dosage administered at Visits 3, 4, and 5 for which data was available.

    Plasma concentrations of the active substance of APL-130277, apomorphine, were analysed using a validated LC-MS/MS assay, with a lower limit of quantification of 0.020 ng/mL.


  7. PK Evaluation: Time to Last Analytically Quantifiable Concentration (Tlast) [ Time Frame: Just prior to dosing and at 10, 20, 30, 45, 60 and 90 minutes after each dose at Visits 3 - 5. ]

    The mean Tlast values are presented for each dosage administered at Visits 3, 4, and 5 for which data was available.

    Plasma concentrations of the active substance of APL-130277, apomorphine, were analysed using a validated LC-MS/MS assay, with a lower limit of quantification of 0.020 ng/mL.


  8. PK Evaluation: Area Under the Plasma Concentration Time Curve, From Time 0 to 90 Minutes (AUC0-90) [ Time Frame: Just prior to dosing and at 10, 20, 30, 45, 60 and 90 minutes after each dose at Visits 3 - 5. ]

    The mean AUC0-90 values are presented for each dosage administered at Visits 3, 4, and 5 for which data was available.

    Plasma concentrations of the active substance of APL-130277, apomorphine, were analysed using a validated LC-MS/MS assay, with a lower limit of quantification of 0.020 ng/mL.


  9. PK Evaluation: Area Under the Plasma Concentration Time Curve, From Time 0 to the Last Measurable Non-zero Concentration (AUClast) [ Time Frame: Just prior to dosing and at 10, 20, 30, 45, 60 and 90 minutes after each dose at Visits 3 - 5. ]

    The mean AUClast values are presented for each dosage administered at Visits 3, 4, and 5 for which data was available.

    Plasma concentrations of the active substance of APL-130277, apomorphine, were analysed using a validated LC-MS/MS assay, with a lower limit of quantification of 0.020 ng/mL. The AUClast was calculated by a combination of linear and logarithmic trapezoidal methods (linear up/log down method).



Secondary Outcome Measures :
  1. Percentage Change in MDS-UPDRS Section III Score From Pre-dose Assessment [ Time Frame: At 15, 30, 45, 60 and 90 minutes after dosing at Visits 3 - 5. ]
    The Motor Function section (Section III) of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) included 33 scores based on 18-items, each anchored with 5 responses: 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. The scale range was from 0 to 132, with a lower score indicating better motor function and a higher score indicating more severe motor symptoms. The percent change in the MDS-UPDRS Section III score from pre-dose to the first full ON dose or last dose for non-responders is presented. A negative change from baseline indicates an improvement.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female ≥18 years of age.
  2. Clinical diagnosis of Idiopathic PD
  3. Receiving stable doses of L-dopa +/- other adjunctive PD therapy for at least 4 weeks before study participation.
  4. At least one OFF episode per day and a total daily OFF time of > 2 hours duration.
  5. Experience predictable OFF episodes in the morning on awakening prior to receiving morning dose of levodopa.
  6. Stage I to III on the Hoehn and Yahr scale in the "ON" state.
  7. If female and of childbearing potential, must agree to use one of the following methods of birth control:
  8. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study.
  9. Able to understand the consent form, and to provide written informed consent.

Exclusion Criteria:

  1. Atypical or secondary parkinsonism
  2. Changes in L-dopa or other PD drug dosing regimens 4 weeks before the screening visit.
  3. Past treatment with any form of apomorphine within 30 days of Dosing Day 1 (patients who stopped apomorphine for reasons other than lack of efficacy OR tolerability issues may be considered for the trial).
  4. Female who is pregnant or lactating.
  5. Contraindications to APOKYN or hypersensitive to apomorphine hydrochloride or any of the ingredients of APOKYN (notably sodium metabisulfite), or Tigan®.
  6. Participation in any other clinical trial within 14 days of the screening visit.
  7. Receipt of any investigational (i.e., unapproved) medication within 30 days of the screening visit.
  8. Currently taking, or likely to need to take at any time during the course of the study
  9. Currently taking dopamine antagonists or depleting drugs excluding anticholinergics and/or antihistamines with anticholinergic effects.
  10. Drug or alcohol dependency in the past 6 months.
  11. Clinically significant orthostatic hypotension.
  12. Malignant melanoma or a history of previously treated malignant melanoma within 5 years.
  13. Clinically significant medical surgical or laboratory abnormality in the judgment of the investigator.
  14. Psychiatric disorder, including but not limited to dementia or any disorder that, in the opinion of the Investigator requires ongoing treatment that would make study participation unsafe or make treatment compliance difficult.
  15. Dementia that precludes providing informed consent.
  16. Potential for lack of compliance and follow-up in the judgment of the investigator.
  17. Any other condition, current therapy, or prior therapy (within 30 days of the screening visit), which, in the opinion of the Investigator, would make the subject unsuitable for the study.
  18. Previous neurosurgery for PD.
  19. Donation of blood or plasma in the 30 days prior to dosing.
  20. Presence of cankers or mouth sores.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02228590


Locations
Layout table for location information
United States, Arizona
Banner Sun Health Research Institute
Sun City, Arizona, United States, 85351
United States, Colorado
Rocky Mountain Movement Disorders Center
Englewood, Colorado, United States, 80113
United States, Florida
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, United States, 33486
University of South Florida Parkinson's Disease and Movement Disorders Center
Tampa, Florida, United States, 33613
Sponsors and Collaborators
Sunovion
Investigators
Layout table for investigator information
Study Director: CNS Medical Director Sunovion
  Study Documents (Full-Text)

Documents provided by Sunovion:
Study Protocol  [PDF] September 10, 2014
Statistical Analysis Plan  [PDF] June 2, 2015

Layout table for additonal information
Responsible Party: Sunovion
ClinicalTrials.gov Identifier: NCT02228590    
Other Study ID Numbers: CTH-105
First Posted: August 29, 2014    Key Record Dates
Results First Posted: July 30, 2020
Last Update Posted: July 30, 2020
Last Verified: July 2020
Keywords provided by Sunovion:
Parkinson's Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Apomorphine
Emetics
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action